Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Nakamura, Ikuo ^a   Zakharia, Kais ^a   Banini, Bubu A ^a   Mikhail, Dalia S ^a   Kim, Tae Hyo ^a   Yang, Ju Dong ^a   Moser, Catherine D ^a   Shaleh, Hassan M ^a   Thornburgh, Sarah R ^a   Walters, Ian ^b   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BRIVANIB; COLLAGEN; COLLAGEN TYPE 1 ALPHA1; FIBROBLAST GROWTH FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG; VASCULOTROPIN; ALANINE; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; PROTEIN KINASE INHIBITOR; TRIAZINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STELLATE CELL; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CARBON TETRACHLORIDE POISONING; CELL LINE; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLISM; PATHOLOGY;

ALANINE; ANIMALS; CARBON TETRACHLORIDE POISONING; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLLAGEN TYPE I; FIBROBLAST GROWTH FACTORS; HEPATIC STELLATE CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; PLATELET-DERIVED GROWTH FACTOR; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899440060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092273     Document Type: Article

References (28)

1. Sokolovic A, Sokolovic M, Boers W, Elferink RP, Bosma PJ (2010) Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair 3: 3.
2. Yang JD, Nakamura I, Roberts LR (2011) The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol 21: 35-43.
3. Campbell JS, Hughes SD, Gilbertson DG, Palmer TE, Holdren MS, et al. (2005) Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 102: 3389-3394. (Pubitemid 40328055)
4. Bartok I, Remenar, Toth J, Duschanek P, Kanyar B (1981) Clinicopathological studies of liver cirrhosis and hepatocellular carcinoma in a general hospital. Hum Pathol 12: 794-803.
5. Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, et al. (1990) TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 61: 1137-1146.
6. Kim SO, Park JG, Lee YI (1996) Increased expression of the insulin-like growth factor I (IGF-I) receptor gene in hepatocellular carcinoma cell lines: implications of IGF-I receptor gene activation by hepatitis B virus X gene product. Cancer Res 56: 3831-3836.
7. Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, et al. (2002) A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol 160: 2295-2307. (Pubitemid 34663420)
8. Torimura T, Sata M, Ueno T, Kin M, Tsuji R, et al. (1998) Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma. Hum Pathol 29: 986-991. (Pubitemid 28422048)
9. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S (2002) Roles of TGF-beta in hepatic fibrosis. Front Biosci 7: d793-807.
10. Pinzani M, Marra F, Carloni V (1998) Signal transduction in hepatic stellate cells. Liver 18: 2-13. (Pubitemid 28127751)
11. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, et al. (2006) Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 45: 419-428. (Pubitemid 44142114)
12. Liu X, Hu H, Yin JQ (2006) Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 26: 8-22.
13. Yu C, Wang F, Jin C, Huang X, Miller DL, et al. (2003) Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 163: 1653-1662. (Pubitemid 37175112)
14. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, et al. (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14: 6146-6153.
15. Mise M, Arii S, Higashituji H, Furutani M, Niwano M, et al. (1996) Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 23: 455-464. (Pubitemid 26087158)
16. Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, et al. (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49: 2143-2146.
17. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, et al. (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9: 369-378.
18. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, et al. (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2- aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51: 1976-1980. (Pubitemid 351438880)
19. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, et al. (2012) Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18: 2090-2098.
20. Xu L, Hui AY, Albanis E, Arthur MJ, O'Byrne SM, et al. (2005) Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142-151. (Pubitemid 40007234)
21. Kahraman A, Barreyro FJ, Bronk SF, Werneburg NW, Mott JL, et al. (2008) TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 47: 1317-1330. (Pubitemid 351547918)
22. Muller A, Machnik F, Zimmermann T, Schubert H (1988) Thioacetamide- induced cirrhosis-like liver lesions in rats-usefulness and reliability of this animal model. Exp Pathol 34: 229-236.
23. Fibbi G, Pucci M, Grappone C, Pellegrini G, Salzano R, et al. (1999) Functions of the fibrinolytic system in human Ito cells and its control by basic fibroblast and platelet-derived growth factor. Hepatology 29: 868-878. (Pubitemid 29109603)
24. Liu Y, Lui EL, Friedman SL, Li L, Ye T, et al. (2009) PTK787/ZK22258 attenuates stellate cell activation and hepatic fibrosis in vivo by inhibiting VEGF signaling. Lab Invest 89: 209-221.
25. Jeong WI, Park O, Radaeva S, Gao B (2006) STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity. Hepatology 44: 1441-1451. (Pubitemid 44953650)
26. Liu Y, Wen XM, Lui EL, Friedman SL, Cui W, et al. (2009) Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest 89: 1152-1160.
27. Pinzani M (2002) PDGF and signal transduction in hepatic stellate cells. Front Biosci 7: d1720-1726.
28. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS (2007) Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 67: 6899-6906. (Pubitemid 47105537)